Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Post-surgery ctDNA positivity and zero-conversion are highly predictive of recurrence, offering a window for personalised modification of adjuvant therapy.
Authors
- Wei Yen Chan (ORCID: https://orcid.org/0000-0002-8657-2995)
- Helen Rizos (ORCID: https://orcid.org/0000-0002-2094-9198)
- Russell J. Diefenbach (ORCID: https://orcid.org/0000-0002-8433-4336)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Ashleigh Stewart (ORCID: https://orcid.org/0000-0001-5676-1982)
- Richard A. Scolyer (ORCID: https://orcid.org/0000-0002-8991-0013)
- Christian U. Blank (ORCID: https://orcid.org/0000-0002-7945-5846)
- Jenny Lee (ORCID: https://orcid.org/0000-0001-8844-3444)
- Maria Gonzalez (ORCID: https://orcid.org/0000-0002-2197-6657)
- Alexander M. Menzies
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Leiden University Medical Center (NL)
- Royal North Shore Hospital (AU)
- The Netherlands Cancer Institute (NL)
- University Hospital Regensburg (DE)
- Chris O’Brien Lifehouse (AU)
- Melanoma Institute Australia (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1186/s13046-024-03153-1
- Citations
- 19
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Macquarie University
- Melanoma Institute Australia
- Tour de Cure
- Medical Research Council
- National Health and Medical Research Council